Ranbaxy Laboratories surged 5.27 per cent to close at Rs 494.20 after the company announced a drug discovery and development tie-up with global pharma company Merck.

<tr><td><p class='TableClas'></p><P class='TableClas'> <DIV CLASS=rightDiv><script language="JavaScript">
		google_ad_client = 'businessstandard';
		//google_ad_client = 'ca-businessstandard_js';
		google_ad_width = 200;
		google_ad_height = 200;
		google_ad_format = "200x200_as";
		google_ad_type = "text";
		google_ad_channel = "";
		//google_color_border = "FFFFFF";
		google_color_border = "F7F7F7";
		//google_color_bg = "FFFFFF";
		google_color_bg = "ffffff";
		//google_color_link = "639ACE";
		google_color_link = "0253B7";
		google_color_text = "000000";
		google_color_url = "D63431";
		//google_skip = adsenseSkip;
		</script> 
		<script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
		</script> </DIV><p class='TableClas'>Ranbaxy will be paid an undisclosed upfront amount, with the possibility of receiving more than Rs 400 crore associated with various research, development and regulatory approvals, the generic drug maker said. 
</p><p class='TableClas'>The counter witnessed total volumes of 6.11 lakh shares against two-week average volumes of 2.09 lakh shares. The stock made an intra-day high of Rs 497 and a low of Rs 463.20. </P></p></table>


Ranbaxy soars after drug discovery tie-up

DALAL STREET SPIKES

More From This Section

Idea shares fall after Q3 earnings disappoint

BofA-Merrill raises Indiabulls to 'buy', stock gains

Suzlon stocks jump 17% on CDR approval

Maruti Suzuki rallies as Q3 profit beats analyst's estimates

Explore News